White Papers
To remain competitive and to take advantage of the latest innovations, life science companies can’t afford to ignore opportunities in South Korea.
PharmaVentures has successfully completed over 30 projects for South Korean biotechs and pharma companies over the last 5 years and is recognised as a leading western transaction advisory firm in the region.
In this white paper, we look at the significant innovative drug development that has taken place within South Korea during the last decade, and how we can use our experience in this area to help Western pharma and biotech companies meet their pipeline needs by accessing the companies at the cutting edge of our industry.
White Papers
More important than ever, but there’s still a way to go.
Just the other week, it was announced that Illumina had acquired GRAIL (subject to approval from the regulators), a company it formed in 2016 and spun out. Illumina retained a 12% stake in the business and has decided the time is now right to bring it back into the fold. History repeats itself in that the deal took place (as with most diagnostics) at a point at which the technology was in market, or at least market ready. The GRAIL, Galleri diagnostic test, is available as a CLIA waived test to detect 50 different cancers before symptoms appear. The test is yet to be FDA approved or reimbursed and currently costs just under $1000, but this milestone achievement, off the back of more than $2B in investment and a research effort that covered more than 100,000 people, was sufficient to make Illumina want to pay around $8B to reacquire the business.
White Papers
Getting your opportunity noticed by a large pharmaceutical company is difficult, as they are continually bombarded by partnering opportunities daily. PharmaVentures has developed a unique expertise in getting their clients’ opportunities through the complex processes of decision making in the pharmaceutical companies and ultimately in front of their key decision makers, but there is more to it than that.
White Papers
NSCLC is one of the most active areas of innovation in Oncology, and recent consensus estimates indicate that an additional $20BN of sales could be added in the indication over the next few years.
